<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919863</url>
  </required_header>
  <id_info>
    <org_study_id>ATXA-CT001</org_study_id>
    <nct_id>NCT04919863</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of NTP42:KVA4</brief_title>
  <official_title>A Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of NTP42:KVA4 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ATXA Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hammersmith Medicines Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ATXA Therapeutics Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics of&#xD;
      NTP42:KVA4 following oral administration in a randomized, double-blind, placebo-controlled&#xD;
      trial. The trial will involve of 2 phases, a single ascending dose (SAD) phase and a multiple&#xD;
      ascending dose (MAD) phase. The SAD phase will incorporate a food effect arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of single and repeated doses of NTP42:KVA4 in healthy volunteers.</measure>
    <time_frame>Up to 48-hour post-dose.</time_frame>
    <description>Adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the pharmacokinetics of single and repeated doses of NTP42:KVA4 in healthy volunteers.</measure>
    <time_frame>Predose, 0.16, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hours post-dosing.</time_frame>
    <description>Pharmacokinetic parameter: Area under the Curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the effect of food on the pharmacokinetics of NTP42:KVA4 in healthy volunteers.</measure>
    <time_frame>Predose, 0.16, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hours post-dosing.</time_frame>
    <description>Pharmacokinetic parameter: Area under the Curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pharmacodynamics effects of NTP42:KVA4 in healthy volunteers.</measure>
    <time_frame>Predose, 0.75, 2, 4, 8, 12 &amp; 24 hours post-dosing</time_frame>
    <description>TXA2-induced platelet aggregometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NTP42:KVA4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTP42:KVA4</intervention_name>
    <description>Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.</description>
    <arm_group_label>NTP42:KVA4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A body mass index (BMI) in the range 18.0-30.0.&#xD;
&#xD;
          -  Ability &amp; willingness to provide written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant abnormal medical history, physical findings, laboratory values at&#xD;
             pre-trial screening.&#xD;
&#xD;
          -  History of bleeding disorders, coagulation variables or abnormal blood cell count.&#xD;
&#xD;
          -  History of chronic illness.&#xD;
&#xD;
          -  Impaired endocrine, thyroid, hepatic, renal or respiratory function, diabetes&#xD;
             mellitus, coronary heart disease or history of any psychotic mental illness.&#xD;
&#xD;
          -  History of adverse reaction or allergy to any drug.&#xD;
&#xD;
          -  Use of aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), or any other&#xD;
             medicine that affects platelet function or coagulation, or any prescription medicine,&#xD;
             during the 28 days before the first dose of trial medication.&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
&#xD;
          -  Smoker or use of nicotine-containing products&#xD;
&#xD;
          -  Blood pressure or heart rate at screening outside normal ranges.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Boyce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Reserach</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malcolm Boyce, MD</last_name>
    <phone>+44 (0) 20 8961 4130</phone>
    <email>HMR@hmrlondon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Switchboard</last_name>
      <phone>+44 (0) 20 8961 4130</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

